A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3

Zhefan Stephen Chen; Xiaoying Huang; Kevin Talbot; Ho Yin Edwin Chan

doi:10.1038/s41419-021-03444-x

journal article Open Access Feb 02, 2021

A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3

Zhefan Stephen Chen

Xiaoying Huang

Kevin Talbot

Ho Yin Edwin Chan

Cell Death & Disease Vol. 12 No. 2 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41419-021-03444-x

Abstract

AbstractPolyglutamine (polyQ) diseases comprise Huntington’s disease and several subtypes of spinocerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3). The genomic expansion of coding CAG trinucleotide sequence in disease genes leads to the production and accumulation of misfolded polyQ domain-containing disease proteins, which cause cellular dysfunction and neuronal death. As one of the principal cellular protein clearance pathways, the activity of the ubiquitin–proteasome system (UPS) is tightly regulated to ensure efficient clearance of damaged and toxic proteins. Emerging evidence demonstrates that UPS plays a crucial role in the pathogenesis of polyQ diseases. Ubiquitin (Ub) E3 ligases catalyze the transfer of a Ub tag to label proteins destined for proteasomal clearance. In this study, we identified an E3 ligase, pre-mRNA processing factor 19 (Prpf19/prp19), that modulates expanded ataxin-3 (ATXN3-polyQ), disease protein of SCA3, induced neurodegeneration in both mammalian and Drosophila disease models. We further showed that Prpf19/prp19 promotes poly-ubiquitination and degradation of mutant ATXN3-polyQ protein. Our data further demonstrated the nuclear localization of Prpf19/prp19 is essential for eliciting its modulatory function towards toxic ATXN3-polyQ protein. Intriguingly, we found that exocyst complex component 7 (Exoc7/exo70), a Prpf19/prp19 interacting partner, modulates expanded ATXN3-polyQ protein levels and toxicity in an opposite manner to Prpf19/prp19. Our data suggest that Exoc7/exo70 exerts its ATXN3-polyQ-modifying effect through regulating the E3 ligase function of Prpf19/prp19. In summary, this study allows us to better define the mechanistic role of Exoc7/exo70-regulated Prpf19/prp19-associated protein ubiquitination pathway in SCA3 pathogenesis.

Topics

No keywords indexed for this article. Browse by subject →

References

58

[1]

Lieberman, A. P., Shakkottai, V. G. & Albin, R. L. Polyglutamine repeats in neurodegenerative diseases. Annu Rev. Pathol. 14, 1–27 (2019). 10.1146/annurev-pathmechdis-012418-012857

[2]

Stoyas, C. A. & La Spada, A. R. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology. Handb. Clin. Neurol. 147, 143–170 (2018). 10.1016/b978-0-444-63233-3.00011-7

[3]

McLoughlin, H. S., Moore, L. R. & Paulson, H. L. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol. Dis. 134, 104635 (2020). 10.1016/j.nbd.2019.104635

[4]

Seidel, K. et al. On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3. Brain Pathol. 27, 345–355 (2017). 10.1111/bpa.12412

[5]

Matos, C. A., de Almeida, L. P. & Nobrega, C. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. J. Neurochem. 148, 8–28 (2019). 10.1111/jnc.14541

[6]

Chen, Z. S. & Chan, H. Y. E. Transcriptional dysregulation in neurodegenerative diseases: who tipped the balance of Yin Yang 1 in the brain? Neural Regen. Res. 14, 1148–1151 (2019). 10.4103/1673-5374.251193

[7]

Xiang, C., Zhang, S., Dong, X., Ma, S. & Cong, S. Transcriptional dysregulation and post-translational modifications in polyglutamine diseases: from pathogenesis to potential therapeutic strategies. Front Mol. Neurosci. 11, 153 (2018). 10.3389/fnmol.2018.00153

[8]

Chou, A. H. et al. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis. 31, 89–101 (2008). 10.1016/j.nbd.2008.03.011

[9]

Schmidt, T. et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann. Neurol. 51, 302–310 (2002). 10.1002/ana.10101

[10]

Mishra, A. et al. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J. Biol. Chem. 283, 7648–7656 (2008). 10.1074/jbc.m706620200

[11]

Yang, H. et al. PolyQ-expanded huntingtin and ataxin-3 sequester ubiquitin adaptors hHR23B and UBQLN2 into aggregates via conjugated ubiquitin. FASEB J. 32, 2923–2933 (2018). 10.1096/fj.201700801rr

[12]

Chhangani, D. et al. Mahogunin ring finger 1 suppresses misfolded polyglutamine aggregation and cytotoxicity. Biochim Biophys. Acta 1842, 1472–1484 (2014). 10.1016/j.bbadis.2014.04.014

[13]

Lee, B. H. et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179–184 (2010). 10.1038/nature09299

[14]

Wang, H. L. et al. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse. Neuropharmacology 70, 1–11 (2013). 10.1016/j.neuropharm.2013.01.006

[15]

Zheng, N. & Shabek, N. Ubiquitin ligases: structure, function, and regulation. Annu Rev. Biochem. 86, 129–157 (2017). 10.1146/annurev-biochem-060815-014922

[16]

Buetow, L. & Huang, D. T. Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 17, 626–642 (2016). 10.1038/nrm.2016.91

[17]

Ashraf, N. S. et al. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the spinocerebellar ataxia type 3 disease protein. Neurobiol. Dis. 137, 104697 (2020). 10.1016/j.nbd.2019.104697

[18]

Chen, Z. S., Wong, A. K. Y., Cheng, T. C., Koon, A. C. & Chan, H. Y. E. FipoQ/FBXO33, a cullin-1-based ubiquitin ligase complex component modulates ubiquitination and solubility of polyglutamine disease protein. J. Neurochem. 149, 781–798 (2019). 10.1111/jnc.14669

[19]

Ajuh, P. et al. Functional analysis of the human CDC5L complex and identification of its components by mass spectrometry. EMBO J. 19, 6569–6581 (2000). 10.1093/emboj/19.23.6569

[20]

Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N. & Nakayama, K. I. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 33111–33120 (2001). 10.1074/jbc.m102755200

[21]

Ohi, M. D., Vander Kooi, C. W., Rosenberg, J. A., Chazin, W. J. & Gould, K. L. Structural insights into the U-box, a domain associated with multi-ubiquitination. Nat. Struct. Biol. 10, 250–255 (2003). 10.1038/nsb906

[22]

Vander Kooi, C. W. et al. The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases. Biochemistry 45, 121–130 (2006). 10.1021/bi051787e

[23]

Zheng, J. et al. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Nat. Genet. 48, 747–757 (2016). 10.1038/ng.3568

[24]

Song, E. J. et al. The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev. 24, 1434–1447 (2010). 10.1101/gad.1925010

[25]

Das, T. et al. USP15 regulates dynamic protein-protein interactions of the spliceosome through deubiquitination of PRP31. Nucleic Acids Res. 45, 4866–4880 (2017).

[26]

Urano, Y. et al. Involvement of the mouse Prp19 gene in neuronal/astroglial cell fate decisions. J. Biol. Chem. 281, 7498–7514 (2006). 10.1074/jbc.m510881200

[27]

Yamada, T. et al. The U-box-type ubiquitin ligase PRP19beta regulates astrocyte differentiation via ubiquitination of PTP1B. Brain Res. 1524, 12–25 (2013). 10.1016/j.brainres.2013.06.007

[28]

Pei, W. et al. Isolation and identification of a novel anti-protein aggregation activity of lignin-carbohydrate complex from Chionanthus retusus leaves. Front Bioeng. Biotechnol. 8, 573991 (2020). 10.3389/fbioe.2020.573991

[29]

Chan, W. M. et al. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1. Hum. Mol. Genet. 20, 1738–1750 (2011). 10.1093/hmg/ddr049

[30]

Tsoi, H., Lau, T. C., Tsang, S. Y., Lau, K. F. & Chan, H. Y. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl Acad. Sci. Usa. 109, 13428–13433 (2012). 10.1073/pnas.1204089109

[31]

Chow, W. N., Luk, H. W., Chan, H. Y. & Lau, K. F. Degradation of mutant huntingtin via the ubiquitin/proteasome system is modulated by FE65. Biochem J. 443, 681–689 (2012). 10.1042/bj20112175

[32]

Ding, Y. et al. Exo70E2 is essential for exocyst subunit recruitment and EXPO formation in both plants and animals. Mol. Biol. Cell. 25, 412–426 (2014). 10.1091/mbc.e13-10-0586

[33]

Chai, Y., Koppenhafer, S. L., Bonini, N. M. & Paulson, H. L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 19, 10338–10347 (1999). 10.1523/jneurosci.19-23-10338.1999

[34]

Lim, K. L. et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 25, 2002–2009 (2005). 10.1523/jneurosci.4474-04.2005

[35]

Chen, Z. S. et al. Planar cell polarity gene Fuz triggers apoptosis in neurodegenerative disease models. EMBO Rep. 19, e45409 (2018). 10.15252/embr.201745409

[36]

Ellis, M. C., O’Neill, E. M. & Rubin, G. M. Expression of Drosophila glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. Development 119, 855–865 (1993). 10.1242/dev.119.3.855

[37]

Koon, A. C. et al. Drosophila Exo70 is essential for neurite extension and survival under thermal stress. J. Neurosci. 38, 8071–8086 (2018). 10.1523/jneurosci.0620-18.2018

[38]

Warrick, J. M. et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell. 18, 37–48 (2005). 10.1016/j.molcel.2005.02.030

[39]

Warrick, J. M. et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93, 939–949 (1998). 10.1016/s0092-8674(00)81200-3

[40]

Wong, S. L., Chan, W. M. & Chan, H. Y. Sodium dodecyl sulfate-insoluble oligomers are involved in polyglutamine degeneration. FASEB J. 22, 3348–3357 (2008). 10.1096/fj.07-103887

[41]

Zhang, Q. et al. A peptidylic inhibitor for neutralizing r(GGGGCC)exp-associated neurodegeneration in C9ALS-FTD. Mol. Ther. Nucleic Acids 16, 172–185 (2019). 10.1016/j.omtn.2019.02.015

[42]

Wu, Y. L. et al. Treatment with caffeic acid and resveratrol alleviates oxidative stress induced neurotoxicity in cell and Drosophila models of spinocerebellar ataxia type 3. Sci. Rep. 7, 11641 (2017). 10.1038/s41598-017-11839-0

[43]

Schilling, J. et al. Deregulated splicing is a major mechanism of RNA-induced toxicity in Huntington’s disease. J. Mol. Biol. 431, 1869–1877 (2019). 10.1016/j.jmb.2019.01.034

[44]

Dellago, H. et al. Exo70, a subunit of the exocyst complex, interacts with SNEV(hPrp19/hPso4) and is involved in pre-mRNA splicing. Biochem J. 438, 81–91 (2011). 10.1042/bj20110183

[45]

Hong, H. et al. AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models. J. Biol. Chem. 294, 2757–2770 (2019). 10.1074/jbc.ra118.006307

[46]

Zhu, Y., Wu, B. & Guo, W. The role of Exo70 in exocytosis and beyond. Small GTPases. 10, 331–335 (2019). 10.1080/21541248.2017.1328998

[47]

Sugiura, A. et al. A mitochondrial ubiquitin ligase MITOL controls cell toxicity of polyglutamine-expanded protein. Mitochondrion 11, 139–146 (2011). 10.1016/j.mito.2010.09.001

[48]

Ying, Z. et al. Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum. Mol. Genet. 18, 4268–4281 (2009). 10.1093/hmg/ddp380

[49]

Jana, N. R. et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280, 11635–11640 (2005). 10.1074/jbc.m412042200

[50]

Tsou, W. L. et al. Ubiquitination regulates the neuroprotective function of the deubiquitinase ataxin-3 in vivo. J. Biol. Chem. 288, 34460–34469 (2013). 10.1074/jbc.m113.513903

Showing 50 of 58 references

Cited By

13

E3 ubiquitin ligases and deubiquitinases: Promising therapeutic targets for diabetic kidney disease

Yun Wu, Huicheng Jia · 2026

Cellular Signalling

Metrics

13

Citations

58

References

Details

Published: Feb 02, 2021
Vol/Issue: 12(2)
License: View

Authors

Z

Zhefan Stephen Chen

The Chinese University of Hong Kong, School of Life Sciences, Shatin N.T., Hong Kong, China

Cite This Article

Zhefan Stephen Chen, Xiaoying Huang, Kevin Talbot, et al. (2021). A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Cell Death & Disease, 12(2). https://doi.org/10.1038/s41419-021-03444-x

A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3

You May Also Like